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ABSTRACT
Most cancer chemotherapeutic agents are ineffective in a subset of patients; thus, it is
important to consider the role of genetic variation in drug response. Lymphoblastoid cell lines
(LCLs) derived from 1000 Genomes Project populations of diverse ancestries are a useful model
for determining how genetic factors impact variation in cytotoxicity. In our study, LCLs from
three 1000 Genomes Project populations of diverse ancestries were previously treated with
increasing concentrations of eight chemotherapeutic drugs and cell growth inhibition was
measured at each dose with half-maximal inhibitory concentration (IC50) or area under the doseresponse curve (AUC) as our phenotype for each drug. We conducted genome-wide (GWAS),
transcriptome-wide (TWAS), protein-based association studies (PAS) within and across ancestral
populations. We identified four unique loci with GWAS, three genes with TWAS, and seven
proteins with PAS significantly associated with chemotherapy-induced cytotoxicity within and
across ancestral populations. For etoposide, increased STARD5 predicted expression associated
with decreased etoposide IC50 (p = 8.5 x 10-8). Functional studies in A549, a lung cancer cell
line, revealed that knockdown of STARD5 expression resulted in decreased sensitivity to
etoposide following exposure for 72 (p = 0.033) and 96 hours (p = 0.0001). By identifying loci,
genes, and proteins associated with cytotoxicity across ancestral populations, we strive to
understand the genetic factors impacting the effectiveness of chemotherapy drugs and to
contribute to the development of future cancer treatment.
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CHAPTER ONE
INTRODUCTION
Cancer Genomics and Treatments
The Cancer Genome and Common Variants
Cancer is a complex disease with genetic, environmental, and lifestyle-based risk factors
and in recent years it has become a leading cause of death globally (Torre et al. 2016). There are
more than 100 distinct types of cancer that can occur across tissues, each with unique genetic
characteristics (Stratton, Campbell, and Futreal 2009). The most common cancer types
worldwide are prostate and lung cancer in men and breast cancer in women (Torre et al. 2016).
Cancer arises when a series of somatic mutations occur within a cell, allowing it to proliferate
without regulation and, in many cases, metastasize (Stratton, Campbell, and Futreal 2009;
Shibata 2012). Currently, more than 350 protein-coding genes in the human genome have been
found to be mutated in various cancer types and likely contribute to cancer development
(Stratton, Campbell, and Futreal 2009). Of these mutations, around 90% have been found to be
dominant in effect, meaning mutation in only one allele will contribute to the cell becoming
cancerous (Stratton, Campbell, and Futreal 2009). Additionally, some types of cancer emerge
when a cell incorporates viral DNA, such as the development of cervical cancer in individuals
that contracted human papilloma virus (Stratton, Campbell, and Futreal 2009).
Of the protein-coding genes that have been implicated in cancer development, some
occur more frequently across cancer types while others are unique to specific tumors. Somatic
1
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mutations in TP53, a tumor suppressor gene, are found in more than half of all human cancers
spanning many tissues including brain, breast, lung, ovarian, and colorectal carcinomas (Olivier,
Hollstein, and Hainaut 2010; Leroy, Anderson, and Soussi 2014). The gene TP53 encodes the
protein p53; wildtype p53 functions to suppress tumor development by regulating transcription
and inducing apoptosis (Ko et al. 2019). Mutations in TP53 commonly occur in the DNAbinding domain of p53, resulting in a reduction in the ability to bind DNA and mediate
transcription in the mutated protein (Baugh et al. 2018). These mutations occur across
approximately 190 codons, most often as missense mutations resulting in single-amino acid
changes rather than as frameshift or nonsense mutations, which are more common in other tumor
suppressor genes (Olivier, Hollstein, and Hainaut 2010; Baugh et al. 2018). Additionally, a
greater number of mutations in TP53 is correlated with increasingly altered structure of the p53
protein, resulting in functional changes that promote a cancerous phenotype (Baugh et al. 2018).
Other tumor suppressor genes commonly implicated in cancer are BRCA1 and BRCA2,
which both regulate transcription and DNA repair in response to damage (Yoshida and Miki
2004). The proteins encoded by BRCA1 and BRCA2 have been found in complexes to repair
double stranded breaks in DNA in addition to having independent functions in transcription
mediation and cell cycle regulation (Yoshida and Miki 2004; Varol et al. 2018). BRCA1 and
BRCA2 mutations are associated with increased susceptibility to breast, ovarian, and prostate
cancers (Yoshida and Miki 2004). As some BRCA mutations are germline, increased cancer
susceptibility is hereditary; women with inherited BRCA mutations therefore have a 45% to 75%
chance of developing breast cancer within their lifetime (Baretta et al. 2016). Breast cancers with
BRCA mutations have also been found to be more aggressive and are correlated with higher
mortality rates (Baretta et al. 2016).
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Although common mutations in tumor suppressor and other cancer-associated genes have
been widely studied, much is still unknown about the mechanisms through which these
mutations promote cancer development and progression. By conducting studies on the cancer
genome, the functions of common mutants associated with cancer development, such as those
arising from TP53 and BRCA, can be better understood. Additionally, genetic studies exploring
the effectiveness of cancer treatments allow for the identification of new variants and genes
associated with treatment phenotypes.
Chemotherapeutic Drugs and Mechanisms
Chemotherapy-based treatments for cancer emerged in the early 1900s; however, use of
chemotherapeutics did not become widespread until the 1960s when studies demonstrated they
could be used to cure more advanced cancers that were less responsive to surgery and radiation
therapy (DeVita and Chu 2008). The discoveries of various chemotherapeutics allowed for
targeted treatments to emerge and adjuvant chemotherapy methods to arise, using multiple
methods of treatment in conjunction to produce better patient outcomes (DeVita and Chu 2008).
A common example of this is the use of chemotherapeutics to reduce the size of the tumor before
surgery, in effort to improve the likelihood of complete extraction and preserve more of the
surrounding healthy tissue (DeVita and Chu 2008). Subsequently, the advancements provided by
chemotherapy have caused cancer mortality rates to continually decline since 1990 (DeVita and
Chu 2008).
Platinum-based drugs are a common class of chemotherapeutics; these include cisplatin,
carboplatin, and oxaliplatin, all of which are widely used to treat various cancer types (Hato et al.
2014). The reactive platinum in these drugs is able to covalently bind to DNA to form platinum-
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DNA adducts, which disrupt DNA repair mechanisms, causing cancerous cells to induce
apoptosis (Dasari and Tchounwou 2014; Hato et al. 2014). Recent studies have found that
platinum-based chemotherapeutics may also have anticancer effects as a result of immune
system modulation (Hato et al. 2014). Treatments with platinum-based drugs have been found to
enhance T-cell activation, strengthening the immune response towards cancerous cells, and to
regulate the phosphorylation of STAT signaling proteins that then interact with programmed
death receptors to induce cell death (Hato et al. 2014). However, platinum-based
chemotherapeutics also come with challenges. For cisplatin in particular, negative side effects
can occur, including severe kidney problems, hearing loss, gastrointestinal disorders, and
hemorrhage (Dasari and Tchounwou 2014). Additionally, cisplatin-resistance is common; thus,
combination therapies with radiation or other chemotherapeutics are used to provide effective
treatment of resistant tumors (Dasari and Tchounwou 2014).
One drug often used jointly with cisplatin to treat resistant tumors is paclitaxel. Paclitaxel
was found to be an effective anticancer drug in the 1980s when a clinical study found 30% of
patients with advanced ovarian cancer responded positively to treatment (Weaver 2014).
Currently, paclitaxel is used primarily to treat breast, ovarian, and lung cancers (Weaver 2014;
Zhu and Chen 2019). Paclitaxel inhibits microtubule production by reducing the concentration of
tubulin subunits in the cell and it also binds to existing microtubules and interferes with their
function in cell division, leading to mitotic arrest and, ultimately, cell death (Weaver 2014; Abu
Samaan et al. 2019). Paclitaxel also has positive immunological effects, as it promotes the
activation and proliferation of T cells and natural killer cells, bolstering the body’s own immune
response to cancer cells (Zhu and Chen 2019). Resistant ovarian cancers treated with a
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combination of cisplatin and paclitaxel had a 73% better response rate than those treated with
cisplatin alone (Dasari and Tchounwou 2014).
Another common class of chemotherapeutics are antineoplastic drugs; these inhibit DNA
topoisomerases, which are responsible for cutting and pasting both single- and double-stranded
DNA (Hande 1998). The antineoplastic drug etoposide inhibits topoisomerase II, disrupting
DNA replication, recombination, and transcription in malignant cells, resulting in increased
DNA degradation and apoptosis (Hande 1998). Etoposide is used to treat both small and nonsmall cell lung cancers, gastric and testicular cancers, and lymphoma, with response rates
ranging from 10% to 45% (Hande 1998).
Although chemotherapy is a widely effective treatment for various cancer types,
limitations exist. Varied patient responses, including the development of drug-resistant tumors
that require combination therapies, and the degree of tumor progression both impact the success
of chemotherapy treatments (Galmarini, Galmarini, and Galmarini 2012; Stordal et al. 2012;
Marin et al. 2009). Moreover, finding effective treatments for metastatic cancer is especially
challenging, despite recent developments in targeted therapy and cancer immunology. (Roy and
Saikia 2016; Galmarini, Galmarini, and Galmarini 2012). Therefore, personalized approaches to
cancer medicine that deepen our understanding of the genetic variants and biological
mechanisms impacting a patient’s response to treatment are necessary in order to successfully
cure advanced cancers (Jackson and Chester 2015).
Lymphoblastoid Cell Lines
One method for identifying factors that impact drug efficacy and patient response is to
conduct pharmacogenomic studies of chemotherapeutics, which involve treatment with drug,
quantitative measurement of response or cytotoxicity, and statistical analysis of a response or

6
cytotoxicity phenotype in relation to genomic, transcriptomic, or proteomic variation. Cancer
pharmacogenomic studies are often performed using in vitro human cell lines models, including
lymphoblastoid cell lines (LCLs) and cancer cell lines from various tissues (Niu and Wang
2015). LCLs are derived by infecting blood lymphocytes with the Epstein-Barr virus; this
immortalizes the cell population, providing a model that continuously proliferates without
becoming tumorigenic (Hussain and Mulherkar 2012). The widespread availability and relative
affordability of cell lines makes it easier to conduct initial studies with in vitro models rather
than clinically in patients (Niu and Wang 2015; Heather E. Wheeler and Dolan 2012).
LCLs from the International HapMap and 1000 Genomes Projects serve as one effective
model for determining genetic factors contributing to chemotherapeutic cytotoxicity because
they have extensive genetic information and environmental factors can be controlled (Heather E.
Wheeler and Dolan 2012). There are also LCLs derived from a multitude of ancestral
populations making them particularly useful for studying how cytotoxicity varies across
ancestral populations (Heather E. Wheeler and Dolan 2012; International HapMap Consortium
2003; 1000 Genomes Project Consortium et al. 2015). Studies conducted in LCLs do have
limitations though, as complex drug effects and interactions that exist in the body cannot be fully
determined in vitro and treatment with a single drug does not allow for analysis of the factors
contributing to the effectiveness of combination therapies, which are commonly used on lessresponsive tumors (Heather E. Wheeler and Dolan 2012; Roell et al. 2019). Overall, LCLs
provide a promising model for pharmacogenomic studies due to their vast utility, and they have
enabled the identification of variants involved in cancer progression and may contribute to the
development of more effective and personalized cancer treatments.
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Multi-Omics Approaches in Genetic Studies
Genome-Wide Association Studies
Genome-wide association studies (GWAS), which emerged in the early 2000s, are a
powerful computational tool used to identify genotypic variants in the form of single nucleotide
polymorphisms (SNPs) associated with a given phenotype (Bush and Moore 2012; Ku et al.
2010). The human genome contains millions of SNPs that can have significant phenotypic
implications as they can impact RNA transcript stability and cause amino acid changes that could
potentially alter protein structure and function (Bush and Moore 2012). The majority of SNPs
have two alleles, with the major allele occurring with greater frequency than the minor allele in a
given population (Bush and Moore 2012). Commonly occurring alleles generally have lower
penetrance, meaning they have smaller genetic effects (Bush and Moore 2012). Consequently,
the heritability of complex diseases is determined through the combination of a multitude of
alleles, which can be identified with GWAS (Bush and Moore 2012).
Conducting GWAS requires both genotype and phenotype data for a group of
individuals; phenotype data must be measured quantitively and can either be continuous or in the
form of cases and controls (Bush and Moore 2012). GWAS implement linear modeling to test
the null hypothesis that there is no significant difference in phenotype between alleles of a SNP;
millions of SNPs are analyzed and those found to be significantly associated with the phenotype
can then be further investigated (Bush and Moore 2012). As a result of linkage disequilibrium,
which is the non-random correlation of alleles at a given locus, not all SNPs identified through
GWAS will be causal; false positives that appear to associate with the phenotype may occur due
to linkage to the causal SNP (Bush and Moore 2012). Thus, while GWAS are useful for
identifying novel variants associated with complex traits, additional studies are necessary to
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better understand and validate findings so that they may one day be applied to improve
treatment.
As GWAS have become more established, many software tools have been developed to
allow for greater utility and more accurate results. Genome-wide efficient mixed-model
association (GEMMA), which uses linear mixed modeling, is one of those tools (Zhou and
Stephens 2012). GEMMA rapidly produces results even with large sample sizes (Zhou and
Stephens 2012). Additionally, GEMMA can adjust for population-based covariates, including
ancestry and relatedness, which allows for admixed populations to be analyzed and related
individuals to remain in samples rather than be filtered out as they would skew results if not
accounted for (Zhou and Stephens 2012).
Cancer GWAS
The emergence of GWAS provided a novel approach for investigating the role of genetic
variants in cancer. As of 2017, more than 700 SNPs associated with increased risk for various
malignancies had been identified, providing new insight into the heritability of cancer (Sud,
Kinnersley, and Houlston 2017). More than 90% of these variants are located within non-coding
regions of the genome, such as intergenic and intronic regions, rather than in protein-coding
regions, making them challenging to interpret (Chen et al. 2019). However, when the SNPs are
located within protein-coding regions the results can be promising, as further research can then
be conducted on the possible role of gene expression levels, protein functions, and chemical
pathways on cancer development (Sud, Kinnersley, and Houlston 2017; Liang et al. 2020).
In addition to providing insight into the genetics of and biochemical mechanisms
involved in cancer risk, GWAS can also help to contextualize known environmental factors that
can lead to cancer development. Several GWAS identified significant SNPs associated with both
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nicotine dependence and lung cancer susceptibility within the genes CHRNA3, CHRNA5, and
CHRNB4, all of which encode nicotinic acetylcholine receptor subunits (Bossé and Amos 2018).
These findings demonstrate the relationship between smoking, a well-known environmental risk
factor, and lung cancer development, adding to our understanding of how environmental and
genetic components impacting cancer risk are related (Bossé and Amos 2018). While many
significant loci associated with cancer risk have been found, these variants generally have low
penetrance and only account for a small percentage of heritability (Liang et al. 2020). In order to
better understand the genetic factors impacting cancer risk, additional association studies can be
performed to directly identify significant gene expression and protein levels that play a role in
malignancy.
Transcriptome-Wide Association Studies
Although GWAS identify associations at the SNP level, they do not provide insight into
the underlying biochemical mechanisms that regulate traits (Gamazon et al. 2015).
Transcriptome-wide association studies (TWAS) are another method for analyzing factors
impacting phenotype as they identify genes with significant expression levels that can then be
further studied to determine their role in regulating traits (Gamazon et al. 2015; Barbeira et al.
2019; Mogil et al. 2018). One widely used tool for conducting TWAS is PrediXcan, which
employs statistical modeling to predict transcript expression levels from genotypes and
determine associations between predicted gene expression and phenotype (Gamazon et al. 2015).
Through predictive modeling, PrediXcan provides an accessible method to analyze gene
expression levels and their impact on phenotype as the user does not need to have transcript data
but only genomic data, as they would for GWAS, or GWAS summary statistics; this is notable as
it eases the process of studying the transcriptome, which historically has been more challenging
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due to the rapid rate of degradation of RNA samples and human tissue accessibility (Gamazon et
al. 2015; Barbeira et al. 2018).
The prediction models used in PrediXcan were trained with cross-validated Elastic Net
regularization of genotype and transcriptomic data from approximately 20,000 samples from 48
tissue types primarily from the Genotype-Tissue Expression (GTEx) Project (Gamazon et al.
2015). These models can be used to predict tissue-specific gene expression levels from
genotypes and identify associations with phenotypes. Additional predictive models also derived
with Elastic Net were trained with transcriptomic data from monocytes from diverse populations
from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort and tested in independent
cohorts (Mogil et al. 2018; Bild et al. 2002). These models differ from the GTEx models as they
can be used to predict population-specific gene expression levels. Another tool for conducting
TWAS is MulTiXcan, which uses the same GTEx models as PrediXcan but derives results by
aggregating expression levels to find associations across tissues rather than to find tissue-specific
associations (Barbeira et al. 2019). Most importantly, both PrediXcan and MulTiXcan can aid in
contextualizing GWAS results, as they implicate gene regulation in relation to phenotype and
provide the direction of effect for each association. Thus, conducting TWAS in addition to
GWAS enables researchers to better identify the biochemical mechanisms impacting phenotype,
as the combination of associations with SNPs and gene expression levels creates a more cohesive
understanding of the factors regulating traits.
Advantages of Studying Proteomic Variants
Both GWAS and TWAS have become prominent computational tools in the field of
human genetics, enabling scientists to expand their knowledge of the variants impacting complex
traits. Yet, a truly holistic understanding of the biological processes regulating phenotypes
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requires a multi-omics approach where genomic, transcriptomic, and proteomic variants are all
analyzed (Hasin, Seldin, and Lusis 2017; I. Subramanian et al. 2020). While the transcriptome
has been more widely studied due to the larger and more complete nature of transcriptomic data
sets, the proteome has become the subject of more recent analyses as high-throughput
technologies have amassed large proteomic datasets (Liu 2008; Aslam et al. 2017). Proteomic
data is far more dynamic than genomic and even transcriptomic data, as protein expression
levels, structure, and function vary depending on cell type, conditions, and conformations,
whereas genomic data is consistent across cell type and transcriptomic data accounts for
primarily tissue-based expression differences (Manzoni et al. 2018). Moreover, analyzing the
proteome is vital in understanding gene function, as many proteins undergo post-translational
modifications, resulting in complexities in regulation and protein function that studying the
genome and transcriptome alone will not account for (Aslam et al. 2017). Thus, the intricacies of
the proteome can provide clarity into the biological mechanisms underlying disease development
and progression, while also challenging us to create methods of analysis accounting for greater
degrees of complexity.
Computational omics studies all rely on statistical testing to identify significant
associations with phenotype; when testing integrates multi-omics data the results can be
compared across the genome, transcriptome, and proteome to identify novel regulating pathways
and find commonalties that further implicate and contextualize mechanisms (Hasin, Seldin, and
Lusis 2017; I. Subramanian et al. 2020). Although progress have been made in the development
of software tools designed for proteomic studies, there are still advancements needed to improve
performance and expand the degree with which the full proteome can be studied (Aslam et al.
2017). Protein-based association studies (PAS), for example, take statistical analysis a step
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beyond TWAS to identify significant proteins associated with a given phenotype; however, the
software tools for performing PAS are still being developed and necessary data is still being
collected, so they are not truly proteome-wide yet, as only a subset of proteins have been
included in predictive modelling or other analysis methods (Okada et al. 2016; Brandes, Linial,
and Linial 2020). Nonetheless, proteomic studies have versatile applications, as their results not
only provide greater insight into the biochemical factors regulating disease risk, but also enable
further analyses into how proteomic variation impacts treatment (Manzoni et al. 2018).
Significant protein associations identified through PAS have more therapeutic application than
significant SNPs or transcripts from genomic and transcriptomic studies, as the functions and
relevant mechanisms of significant proteins can be more directly explored through clinical
experimentation (Doll, Gnad, and Mann 2019; Ahmed 2020). Consequently, when specific
biochemical pathways are implicated, scientists can begin developing more personalized
treatments that effectively target the proteins involved (Ahmed 2020).
One organization seeking to expand access to proteomic data for its utilization in
computational analyses of disease traits is the NHLBI Trans Omics for Precision Medicine
(TOPMed) Consortium (Raffield et al. 2020). The TOPMed Consortium includes proteomic data
from various studies, including the MESA cohort (Bild et al. 2002; Raffield et al. 2020).
Proteomic data was collected for approximately 1,300 proteins from blood plasma samples using
SOMAscan aptamer-based arrays, which measure protein levels through the binding of the target
protein to a specific aptamer (Gold et al. 2010; Raffield et al. 2020). Looking forward, this data
can be used in future studies to find associations between protein levels and diseases, providing
new insight into how omics traits regulate phenotype and their larger role in human health.
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Several studies have investigated the potential applications of proteomic analyses on
cancer precision medicine (Tyanova and Cox 2018; Uzozie and Aebersold 2018; Doll, Gnad, and
Mann 2019; Giudice and Petsalaki 2019). While cancer has been the focus of many other genetic
studies, including GWAS and TWAS that have identified hundreds of significant SNPs and
transcript associations, proteomic studies greatly expand on previous findings, as determining the
functionalities of implicated proteins is more relevant in understanding the mechanisms
regulating complex cancer phenotypes (Doll, Gnad, and Mann 2019). The characterization of
proteins associated with cancer risk and prognosis enables the option of preventative measures
for high-risk patients and the determination of the best course of treatment for patients with
cancer (Tyanova and Cox 2018; Sellami and Bragazzi 2020). Proteomic studies also provide
insight into cancer-specific biochemical pathways, which could potentially be useful in the
development of targeted therapies (Uzozie and Aebersold 2018). Cancer precision medicine has
slowly advanced as computational and clinical pharmacogenomic studies have made beneficial
discoveries; the first cancer drug based on genetic factors rather than tumor or tissue type was
approved by the FDA in 2017 (Doll, Gnad, and Mann 2019). Overall, the use of computational
methods for analyzing the role of proteomic variants in disease risk and treatment is vital, as
future clinical studies can further explore relevant proteins to enable the development of more
effective and personalized treatments.
Diversity in Genetic Studies
In the past two decades, genetic studies have identified and contextualized a myriad of
genomic, transcriptomic, and proteomic variants impacting phenotypes; however, these studies
are often lacking the diversity, as the vast majority of participants are of European ancestries.
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This discrepancy can be illustrated with GWAS, as 81% of participants across the more than
3,000 studies published as of 2018 were of European ancestries (Hindorff et al. 2018). This is
detrimental as alleles and allele frequencies differ across human populations; thus,
disproportionately analyzing data from one ancestral population over others results in fewer
significant variants being identified and some rare variants found only within certain populations
not being included at all (Hindorff et al. 2018). Consequently, this lack of representation hinders
our understanding of how genetic differences affect disease and treatment, limiting the clinical
application of findings, as the bias from studying predominantly European populations yields
incomplete results (Sirugo, Williams, and Tishkoff 2019).
The 1000 Genomes Project (phase 3) aimed to expand diversity in human genetic
research by performing whole-genome sequencing on 26 ancestral populations from around the
world and creating a publicly available platform where the data collected could be accessed and
utilized in genetic studies (1000 Genomes Project Consortium et al. 2015). Through this project,
more than 88 million SNPs were genotyped; notably, African ancestral populations had the
highest proportions of population- and continent-specific SNPs, as well as the greatest total
numbers of SNPs, at about 5 million per genome (1000 Genomes Project Consortium et al.
2015). These populations have since been used in hundreds of studies, which subsequently
implicated a plethora of novel variants in phenotypic regulation (S. L. Park, Cheng, and Haiman
2018). These findings demonstrate that the development of precision medical treatments is
dependent on greater diversity in genetic studies.
Summary
There have been a number of previous studies demonstrating the impacts of genomic
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variation on chemotherapeutic drug response (Niu and Wang 2015; R. S. Huang, Duan, Bleibel,
et al. 2007; H. E. Wheeler et al. 2013; R. S. Huang, Duan, Shukla, et al. 2007; Bleibel et al.
2009; R. S. Huang, Duan, Kistner, Hartford, et al. 2008; R. S. Huang, Duan, Kistner, Bleibel, et
al. 2008; O’Donnell et al. 2012; Hartford et al. 2009). In this project, we sought to expand on
prior findings by conducting GWAS, TWAS and PAS on drug-response phenotypes from eight
chemotherapeutics measured in HapMap LCLs derived from three ancestral populations
consisting of individuals with African, Asian, and European ancestries. By including individuals
of diverse backgrounds in this study, we identified associations both within and across ancestral
populations. Previous GWAS were conducted on subsets of these individuals before the 1000
Genomes Project was complete, thus at that time many individuals had been genotyped through
the HapMap Project but not sequenced (R. S. Huang, Duan, Bleibel, et al. 2007; Bleibel et al.
2009; Komatsu et al. 2015; Gamazon et al. 2013; H. E. Wheeler et al. 2013; R. S. Huang, Duan,
Shukla, et al. 2007; R. S. Huang, Duan, Kistner, Hartford, et al. 2008; O’Donnell et al. 2012; R.
S. Huang, Duan, Kistner, Bleibel, et al. 2008; Gamazon et al. 2018; Hartford et al. 2009; 1000
Genomes Project Consortium et al. 2015; International HapMap Consortium 2003). In this study,
all individuals were either sequenced or imputed with the 1000 Genomes as reference, allowing
more SNPs to be analyzed. We also performed TWAS and PAS on these data for the first time to
discover gene- and protein-based associations and gain further insight into the underlying
mechanisms involved in regulating drug response. Moreover, for the most significant gene
identified, STARD5, we validated our results by performing knockdown experiments in a lung
cancer cell line treated with the associated chemotherapeutic, etoposide. By conducting GWAS,
TWAS, and PAS, confirming our results experimentally, and incorporating diverse ancestral
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populations, we aimed to cultivate a deeper understanding of the genomic factors and
biochemical mechanisms impacting chemotherapy drug response and contribute to the
development of future precision cancer treatment.

CHAPTER TWO
METHODS
Publication disclaimer
This work was previously published in Human Molecular Genetics (2021)
doi.org/10.1093/hmg/ddab029 with the following authors:
Ashley J. Mulford1,2, Claudia Wing3, M. Eileen Dolan3, Heather E. Wheeler1,2
1

Department of Biology, Loyola University Chicago, Chicago, IL, USA, 2Program in
Bioinformatics, Loyola University Chicago, Chicago, IL, USA, 3Section of
Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA

Data Preparation
We procured cytotoxicity phenotypes measured in HapMap LCLs from previous studies
of eight chemotherapy drugs, including ara-C, capecitabine, carboplatin, cisplatin, daunorubicin,
etoposide, paclitaxel, and pemetrexed (R. S. Huang, Duan, Bleibel, et al. 2007; Bleibel et al.
2009; Komatsu et al. 2015; Gamazon et al. 2013; H. E. Wheeler et al. 2013; R. S. Huang, Duan,
Shukla, et al. 2007; R. S. Huang, Duan, Kistner, Hartford, et al. 2008; O’Donnell et al. 2012; R.
S. Huang, Duan, Kistner, Bleibel, et al. 2008; Gamazon et al. 2018; Hartford et al. 2009). These
LCLs were derived from 178 individuals from the Yoruba population in Ibadan, Nigeria (YRI),
178 individuals with European ancestries from Utah, United States (CEU), and 90 individuals
from a combined population of Han Chinese from Beijing, China and Japanese from Tokyo,
Japan (ASN). The YRI population contained 58 parent-child trios and the CEU population
contained 52 parent-child trios, which we accounted for when conducting our genetic analyses.
17
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The numbers of LCLs with measured phenotypes varied for each drug (Table 1). Cellular
sensitivity to each drug was recorded as the area under the dose-response curve (AUC) for ara-C,
capecitabine, paclitaxel, and pemetrexed, and as the half-maximal inhibitory concentration (IC50)
for carboplatin, cisplatin, daunorubicin, and etoposide. These concentrations were all measured
after 72 hours of exposure to the corresponding chemotherapeutic. We rank-normalized (RN) the
AUC or IC50 for use in our subsequent genetic analyses. Additionally, once phenotypic data was
collected for each ancestral population and drug, genotypic data were imputed using BEAGLE;
all genotypes were in Genome Build 37 and only autosomal variants were analyzed (Browning
and Browning 2007).
Table 1. Individuals with genotype and phenotype data. Counts given for each ancestral
population and drug combination.
Population
CEU

YRI

ASN

ALL

Ara-C
(RN AUC)

165

177

90

432

Capecitabine
(RN AUC)

165

175

90

424

Carboplatin
(RN IC50)

168

172

84

430

Cisplatin
(RN IC50)

166

175

90

431

Daunorubicin
(RN IC50)

86

173

0

259

Etoposide
(RN IC50)

84

171

0

255

Paclitaxel
(RN AUC)

77

87

0

164

Pemetrexed
(RN AUC)

84

176

0

260

Drug
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Genome-Wide Association Studies
GWAS with Ancestral Populations
Some individuals with HapMap LCLs used in this study were sequenced in the 1000
Genomes Project and some had genotypes only. Individuals genotyped in HapMap r28, but not
sequenced, were previously imputed to 1000 Genomes (Komatsu et al. 2015). Imputation was
performed using BEAGLE version 3.3.2, which considers the relatedness of the trios in the
imputation (Browning and Browning 2007). We used SNPs with imputation R2 > 0.8, population
minor allele frequency (MAF) > 0.05, and in Hardy–Weinberg equilibrium (P > 1 × 10−6) in our
studies.
Prior to conducting GWAS, we created a relatedness matrix for each of the ancestral
populations, YRI, CEU, and ASN, using GEMMA. For each ancestral population we used the
genotype dosages, with a minimum MAF of 0.05, to calculate the centered relatedness matrix.
We then used GEMMA version 0.98.1 to conduct GWAS using the linear mixed model Wald
test for each ancestral population and corresponding phenotypes (Table 1) (Zhou and Stephens
2012). After conducting GWAS, we created QQ, Manhattan, and LocusZoom plots to aid in
visualizing our results. We made the QQ and Manhattan plots in R using the package qqman and
created the LocusZoom plots with the single plot service on http://locuszoom.org/ (Turner 2014;
Pruim et al. 2010). We made LocusZoom plots for all SNPs with genome-wide significance (p <
5 x 10-8) and we used the corresponding 1000 Genomes Nov. 2014 ancestral population when
generating the LocusZoom plots.
GWAS with Combined Population
To organize data for the ALL population, we combined the BIMBAM files for both the
genotype and phenotype data from each ancestral population into single files. We then used a
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subset of 100,000 SNPs to convert the BIMBAM files into PLINK files, which we needed to
conduct principal components analysis (PCA) with KING (Manichaikul et al. 2010; Purcell et al.
2007). We used the covariates calculated by KING to account for population stratification in the
ALL population. We also plotted the first three principal components to demonstrate that they
accounted for population-based variation (Figure 1). Once these covariates were obtained, we
generated a relatedness matrix for ALL and then conducting GWAS using the same methods as
described for the ancestral populations, with the only difference being the inclusion of the
covariates generated with PCA when conducting GWAS. We generated QQ, Manhattan, and
LocusZoom plots as well, using the same methods (Pruim et al. 2010). As the ALL population
does not correspond to a single 1000 Genomes Nov. 2014 population, we made multiple
LocusZoom plots for each genome-wide significant SNP, each with a different ancestral
population included in the ALL.
Transcriptome-Wide Association Studies
We conducted TWAS with PrediXcan on both the ancestral and combined populations for all
applicable phenotypes, using the GTEx v7 and MESA prediction models (Gamazon et al. 2015;
Mogil et al. 2018; Barbeira et al. 2018). PrediXcan was used to calculate the predicted
expression levels for each gene. We then used GEMMA to perform a total of 7,487,956
association tests, as this enabled us to account for relatedness within the populations with the
matrices created previously. To use GEMMA for this purpose, we reformatted the predicted
expression matrices outputted by PrediXcan into a readable format for GEMMA, so the
association tests could be performed. This produced results specific to each prediction model for
each population and phenotype combination. Additionally, we conducted TWAS with
MulTiXcan for the same populations and phenotypes, using the GTEx v7 prediction models only
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Figure 1. Principal component analysis (PCA) of genotype data. (A) Scree plot showing the
percentage of variance accounted for by each of the ten PCs. (B) PC1 plotted against PC2 for
each individual, colored by ancestral population: ASN, CEU, or YRI. (C) PC1 plotted against
PC3 for each ancestral population. (D) PC2 plotted against PC3 for each ancestral population.
(Barbeira et al. 2019). We did not use GEMMA to conduct these association tests, as MulTiXcan
aggregates across prediction models to find overall associations and GEMMA does not conduct
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the association tests in this manner. Using MulTiXcan, we performed 727,944 association tests
and produced a single set of results for each population and phenotype combination, containing
overall rather than model-specific associations. For the ALL population, we included the
covariates generated from PCA when performing the association tests with both GEMMA and
MulTiXcan to account for population stratification. We then adjusted the p-values derived from
both GEMMA and MulTiXcan using Bonferroni correction, to determine which genes had
significant predicted expression levels associated with drug cytotoxicity. For each significant
gene, we then created predicted expression plots in R using the package ggplot2, which plot the
gene’s predicted expression level against the chemotherapy phenotype (either IC50 or AUC) for
each individual (Wickham 2016).
Gene Set Enrichment Analyses
After performing TWAS on each population and cytotoxicity phenotype, we used the
FUMA tool GENE2FUNC to perform gene set enrichment analysis of the results from
PrediXcan and MulTiXcan (Watanabe et al. 2017). One GENE2FUNC query was made for each
ancestral population and phenotype combination. We submitted two lists of genes for each
query, one for background genes, which contained all the genes analyzed during TWAS, and one
for genes of interest, which contained a significant subset of genes based on either the PrediXcan
or MulTiXcan results we generated previously. To achieve a subset of approximately 100 genes
in each genes of interest list, we used a significance threshold of unadjusted p-value < 0.0005 for
all the PrediXcan results and unadjusted p-value < 0.005 for all the MulTiXcan results. The
PrediXcan results, which were derived from multiple prediction models, were combined so that
the top genes across all models were selected for each ancestral population and phenotype. For
the GENE2FUNC optional parameters, we used all the default options except for gene
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expression data sets, for which we selected GTEx v7: 53 tissue types and GTEx v7: 30 general
tissue types, as these correspond to the prediction models we used when conducting TWAS. We
report significant gene sets that are enriched in each run of PrediXcan or MulTiXcan for each
ancestral population and phenotype with adjusted p (Benjamini-Hochberg FDR) < 0.05.
Gene Knockdown Experiments
Cancer Cell Lines
We obtained non-small cell lung cancer line A549 (CCL-185) from ATCC (Manassas,
VA). IDEXX BioResearch (Columbia, MO) performed authentication of the cancer cell line,
Case # 12135-2020, by using the Promega CELL ID System (Madison, WI) with 8 short tandem
repeat markers (CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, vWA) and
amelogenin (for sex).
Compound preparations
We dissolved etoposide (Sigma-Aldrich, St. Louis, MO) in DMSO to obtain a stock
solution of 10 mM and filtered using a 0.22 µm solvent resistant filter (EMD Millipore, Billerica,
MA, USA) for sterility. We serially diluted the stock in media for final concentrations of 5 to
100 µM for treatment of the A549 cancer cell line. Vehicle control was 0.1% DMSO in media.
Cellular Assay with STARD5 knockdown
We maintained A549 cells in F-12K media (Life Technologies; Carlsbad, CA)
supplemented with 10% FBS (Hyclone, Fisher Scientific; Hanover Park, IL) and 1% PenicillinStreptomycin (Life Technologies). We incubated cultures in a humidified incubator at 37°C with
5% CO2. We performed knockdown of STARD5 using a modified reverse transfection method
(Thermo Fisher “Literature Code: 00189-08-C-01-U”). We mixed ON-TARGETplus
SMARTpool siSTARD5 or ON-TARGETplus non-targeting pool (siSCR) purchased from
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Dharmacon Inc. (Lafayette, CO) with DharmaFECT1 (Dharmacon Inc.) as per manufacturer’s
recommendations to create the transfection mix. We added complete media siSTARD5 or siSCR
complex to produce 25nM final concentrations of each, then added the mixture to a cell pellet
such that the final concentration of cells was 6000 cells/100 µL volume and plated into 96-well
flat bottom tissue culture plates (Cell Star; Quality Biologicals Inc., Gaithersburg, MD). As a
quality control check of the effect of siRNA on cell growth rates, we assayed cell viability using
CellTiter-Glo 2.0 (Promega; Madison, WI), which measures cellular ATP from 0 to 96 hours in
control wells. At 24 hours, we replaced transfection media with media containing increasing
concentrations of etoposide (5 to 100 µM). To determine cellular sensitivity to etoposide in
presence of siSTARD5 or siSCR, we incubated cells with drug for 72 and 96 hours followed by
cell viability assays using CellTiter-Glo 2.0.
Quantitative reverse transcription PCR analysis
At 0, 72, and 96 hours post-drug treatment, we added trypsin to wells of A549 cells
(6,000 cells/well) containing siSTARD5 or siSCR and combined, pelleted, and stored the cells at
-80oC. We extracted RNA using RNeasy Plus (Qiagen; Valencia, CA) and prepared cDNA from
500 ng RNA/sample with the High Capacity cDNA kit (Life Technologies). To determine
STARD5 knockdown in A549 cells, we performed quantitative reverse transcription PCR (qRTPCR) for STARD5, Hs01075234_m1 and a control gene B2M, 4326319E (Life Technologies)
using TaqMan Fast Gene Expression mix (Applied Biosystems; Foster City, CA). We ran each
qRT-PCR in triplicate and determined gene expression levels using the relative standard curve
method on the Viia7 (Life Technologies). We calculated percent knockdown by dividing the
relative STARD5 expression levels in the siSTARD5 sample by the STARD5 expression in the
non-targeting control (siSCR).
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Derivation of Protein-based Prediction Models
We derived new prediction models using protein level data from the MESA cohort
obtained from the TOPMed Consortium. We trained population-based prediction models using
genotype and plasma protein data from a SOMAscan aptamer-based assay of 1335 proteins from
individuals of African (AFA, n = 183), European (EUR, n = 416), Chinese (CHN, n = 71), and
Hispanic/Latino (HIS, n = 301) ancestries in the TOPMed MESA multi-omics pilot study (Bild
et al. 2002; Raffield et al. 2020). A total of five model groups were created from this data,
corresponding to each separate population and one combined population (ALL-M). We used
cross-validated elastic net regularization (alpha mixing parameter=0.5) using the R package
glmnet with genetic variants within 1Mb of the gene encoding each protein as predictors for
protein levels (Friedman, Hastie, and Tibshirani 2010). The models we derived were then tested
in a separate population comprised of individuals of predominately European ancestries. We
created database files, one for each population group, containing all protein models with
Spearman correlation > 0.1 between predicted and observed levels, which were used as the
models in the PAS we conducted. These models are referred to as the TOPMed prediction
models in subsequent sections.
Protein-based Association Studies
We conducted protein-based association studies (PAS) with PrediXcan on both the
ancestral and combined populations for all applicable phenotypes, using the TOPMed prediction
models. As with TWAS, we used PrediXcan to calculate the predicted levels for each protein.
We then reformatted the prediction matrices derived with PrediXcan for GEMMA, which we
used to perform a total of 10,931 association tests, while accounting for relatedness in each
ancestral population. This produced results specific to each prediction model for each population
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and phenotype combination. We used Bonferroni correction to adjust the p-values in each set of
results for multiple testing across models, to identify proteins with predicted levels significantly
associated with cytotoxicity. For each significant protein we created plots in R using the package
ggplot2, displaying the predicted protein levels versus the cytotoxicity phenotype (either IC50 or
AUC) for each individual (Wickham 2016).

CHAPTER THRE
RESULTS
Publication disclaimer
This work was previously published in Human Molecular Genetics (2021)
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Overview of Analyses
In order to investigate genetic and transcriptomic effects on chemotherapeutic toxicity, we
gathered and analyzed previously published dose-response data from LCLs of three diverse
ancestral populations (Komatsu et al. 2015; R. S. Huang, Duan, Bleibel, et al. 2007; Bleibel et al.
2009; Hartford et al. 2009; R. S. Huang, Duan, Shukla, et al. 2007; R. S. Huang, Duan, Kistner,
Hartford, et al. 2008; O’Donnell et al. 2012; Gamazon et al. 2018; H. E. Wheeler et al. 2013; R.
S. Huang, Duan, Kistner, Bleibel, et al. 2008; Gamazon et al. 2013). These LCLs were derived
from 178 individuals from the Yoruba population in Ibadan, Nigeria (YRI), 178 individuals with
European ancestries from Utah, United States (CEU), and 90 individuals from a combined
population of Han Chinese from Beijing, China and Japanese from Tokyo, Japan (ASN). Both the
YRI and CEU populations included parent-child trios. We used phenotypes from eight
27
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chemotherapy drugs in our study. Depending on the drug, the cytotoxicity phenotype from each
individual’s LCL was calculated either with the half-maximal inhibitory concentration (IC50) or
the area under the dose-response curve (AUC). We rank-normalized (RN) these measurements for
use in our genetic analyses. The total counts for individuals with both genotype and phenotype
data varied for each drug and ancestral population. We then performed GWAS, TWAS, PAS, and
gene set enrichment analyses to identify multi-omic traits significantly associated with
chemotherapy-induced cytotoxicity (see overview in Figure 2).
GWAS reveal four loci associated with chemotherapy-induced cytotoxicity
We conducted GWAS using 1000 Genomes Project sequenced and imputed genotypes to
identify genome-wide significant associations between SNPs and the cytotoxicity of each drug
for each ancestral population (YRI, CEU, and ASN) and in all three ancestral populations
combined (ALL) (1000 Genomes Project Consortium et al. 2015). We used GEMMA to perform
univariate linear mixed model GWAS while accounting for relatedness in each ancestral
population and population stratification in the ALL population using covariates generated with
PCA (Zhou and Stephens 2012).We used a threshold p-value = 5 x 10-8 to determine genomewide significance. We found twelve unique SNPs at four independent loci to be significantly
associated with cytotoxicity of four distinct chemotherapeutics, all of which were not previously
implicated in any other GWAS as they do not appear in the GWAS catalog (Table 2) (MacArthur
et al. 2017).
We found two SNPs located in a noncoding region of chromosome four, rs61079639 (p =
2.3 x 10-9) and rs60507300 (p = 2.3 x 10-9), to be associated with daunorubicin cytotoxicity in the
YRI population (Figure 3). We found three SNPs on chromosome nine, rs2100011 (p = 4.7 x 109

), rs2254812 (p = 4.7 x 10-9), and rs2254813 (p = 4.7 x 10-9), to be associated with carboplatin
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Figure 2. Overview of Analyses.
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cytotoxicity in the ASN population (Figure 4). These SNPs are located in the gene PPP1R26;
rs2100011 is an intron variant and rs2254812 and rs2254813 are 5’ untranslated region variants.
Additionally, we found six SNPs located in a noncoding region of chromosome twelve, led by
rs7971310 (p = 1.1 x 10-8), to be associated with etoposide cytotoxicity in the YRI population
(Table 2). Two of these SNPs, rs2711729 (p = 4.9 x 10-8), rs2711728 (p = 4.9 x 10-8), were also
found to be associated with etoposide cytotoxicity in the ALL population (Figure 5). We found
Table 2. Genome-wide significant SNPs (Genome Build 37) from all GWAS performed.
Pop.

Drug

SNP

Chr.

Position

A1

A2

P-value

Beta

YRI

Daunorubicin

rs61079639

4

96611494

T

A

2.3 x 10-9

0.79

YRI

Daunorubicin

rs60507300

4

96611493

T

G

2.3 x 10-9

0.79

ASN

Carboplatin

rs2100011

9

138376145

A

G

4.7 x 10-9

0.77

ASN

Carboplatin

rs2254812

9

138375872

C

G

4.7 x 10-9

0.77

ASN

Carboplatin

rs2254813

9

138375861

G

A

4.7 x 10-9

0.77

YRI

Etoposide

rs7971310

12

47428174

G

A

1.1 x 10-8

-0.85

YRI

Etoposide

rs7960974

12

47424034

A

G

1.1 x 10-8

-0.85

YRI

Etoposide

rs7979399

12

47424033

G

T

1.3 x 10-8

-0.85

YRI

Etoposide

rs2711729

12

47409824

A

G

1.5 x 10-8

0.88

YRI

Etoposide

rs2711728

12

47411926

C

A

1.5 x 10-8

0.88

YRI

Etoposide

rs11183699

12

47426533

A

G

2.6 x 10-8

-0.79

YRI

Cisplatin

rs10510241

3

2907097

A

G

4.7 x 10-8

0.65

ALL

Etoposide

rs2711729

12

47409824

A

G

4.9 x 10-8

0.80

ALL

Etoposide

rs2711728

12

47411926

C

A

4.9 x 10-8

0.80
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Figure 3. GWAS results for YRI and Daunorubicin cytotoxicity phenotype. (A) QQ plot of
GWAS results showing expected vs observed p-values, red line at x=y. (B) Manhattan plot of
GWAS results, red line at genome-wide significance threshold. (C) LocusZoom plot of
rs61079639 (p = 2.3 x 10-9), the blue line measures the recombination rate at a certain position
and each point is colored to indicate linkage disequilibrium (r2) with rs61079639 in the 1000
Genomes Nov. 2014 AFR population.
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Figure 4. GWAS results for ASN and Carboplatin cytotoxicity phenotype. (A) QQ plot of
GWAS results showing expected vs observed p-values, red line at x=y. (B) Manhattan plot of
GWAS results, red line at genome-wide significance threshold. (C) LocusZoom plot of
rs2100011 (p = 4.7 x 10-9), the blue line measures the recombination rate at a certain position and
each point is colored to indicate linkage disequilibrium (r2) with rs2100011 in the 1000 Genomes
Nov. 2014 ASN population.
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Figure 5. GWAS results for ALL and Etoposide cytotoxicity phenotype. (A) QQ plot of GWAS
results showing expected vs observed p-values, red line at x=y. (B) Manhattan plot of GWAS
results, red line at genome-wide significance threshold. (C) LocusZoom plot of rs2711729 (p =
4.9 x 10-8), the blue line measures the recombination rate at a certain position and each point is
colored to indicate linkage disequilibrium (r2) with rs2711729 in the 1000 Genomes Nov. 2014
AFR population.
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one SNP located on chromosome three, rs10510241 (p = 4.7 x 10-8), to be associated with cisplatin
cytotoxicity in the YRI population (Figure 6). This SNP is an intron variant in the gene CNTN4.
No genome-wide significant associations were found for CEU. Through conditional analysis we
found that the SNPs in each chromosomal region were not independent, thus each set of SNPs
represents one association between the corresponding cytotoxicity phenotype and locus. None of
the significant SNPs identified in one ancestral population replicated in another ancestral
population (Table 3).
Table 3. Genome-wide significant SNP results (Genome Build 37) across populations from all
GWAS performed. See Table 2 for chromosome, position, and alleles.

SNP

Drug

YRI
P-value

YRI
Beta

ASN
P-value

ASN
Beta

CEU
P-value

CEU
Beta

ALL
P-value

ALL
Beta

rs61079639

Daunorubicin

2.3 x 10-9

0.79

N/A

N/A

0.59

0.98

3.6 x 10-6

0.84

rs60507300

Daunorubicin

2.3 x 10-9

0.79

N/A

N/A

0.59

0.98

3.6 x 10-6

0.84

rs2100011

Carboplatin

0.29

0.66

4.7 x 10-9

0.77

0.35

0.82

0.0096

0.66

rs2254812

Carboplatin

0.24

0.66

4.7 x 10-9

0.77

0.35

0.82

0.012

0.66

rs2254813

Carboplatin

0.24

0.66

4.7 x 10-9

0.77

0.35

0.82

0.012

0.66

rs7971310

Etoposide

1.1 x 10-8

-0.85

N/A

N/A

0.62

0.95

4.6 x 10-5

0.78

rs7960974

Etoposide

1.1 x 10-8

-0.85

N/A

N/A

0.61

0.60

N/A

N/A

rs7979399

Etoposide

1.3 x 10-8

-0.85

N/A

N/A

0.60

0.60

N/A

N/A

rs2711729

Etoposide

1.5 x 10-8

0.88

N/A

N/A

0.17

0.07

4.9 x 10-8

0.80

rs2711728

Etoposide

1.5 x 10-8

0.88

N/A

N/A

0.17

0.07

4.9 x 10-8

0.80

rs11183699

Etoposide

2.6 x 10-8

-0.79

N/A

N/A

0.64

0.60

6.8 x 10-5

0.77

rs10510241

Cisplatin

4.7 x 10-8

0.65

0.94

0.22

0.94

0.70

7.5 x 10-4

0.61
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Figure 6. GWAS results for YRI and Cisplatin cytotoxicity phenotype. (A) QQ plot of GWAS
results showing expected vs observed p-values, red line at x=y. (B) Manhattan plot of GWAS
results, red line at genome-wide significance threshold. (C) LocusZoom plot of rs10510241 (p =
4.7 x 10-8), the blue line measures the recombination rate at a certain position and each point is
colored to indicate linkage disequilibrium (r2) with rs10510241 in the 1000 Genomes Nov. 2014
AFR population.
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TWAS predict expression of three genes are associated with chemotherapy-induced
cytotoxicity
Following GWAS, we conducted TWAS using both PrediXcan and MulTiXcan to
identify significant associations between predicted gene expression levels and the cytotoxicity of
each drug for each ancestral population (Gamazon et al. 2015; Barbeira et al. 2019). PrediXcan
and MulTiXcan utilize prediction models to calculate predicted expression levels for various
genes and identify associations between predicted gene expression levels and phenotype
(Gamazon et al. 2015; Barbeira et al. 2019). Both PrediXcan and MulTiXcan calculate predicted
gene expression levels for each gene using each model individually, but while PrediXcan then
finds model-specific associations between predicted gene expression and phenotype, MulTiXcan
aggregates expression to find overall associations and identifies models with the best and worst
performance (Gamazon et al. 2015; Barbeira et al. 2019). We used the 48 GTEx version 7 tissuebased prediction models, which each contain approximately 10,000 genes, to run PrediXcan and
MulTiXcan (Gamazon et al. 2015; Barbeira et al. 2019). Additionally, for PrediXcan only, we
used the 5 MESA population-based prediction models, which each contain approximately 8,000
genes (Mogil et al. 2018). To obtain the PrediXcan results, we used PrediXcan to calculate the
predicted gene expression levels and GEMMA to conduct the association tests, as this accounted
for relatedness within each ancestral population (Gamazon et al. 2015; Zhou and Stephens 2012).
To obtain the MulTiXcan results, we used the same predicted gene expression levels and
conducted the association tests with MulTiXcan, as this produced aggregate associations
(Barbeira et al. 2019). For the ALL population, we accounted for population stratification with
the same covariates as in GWAS.
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We found three significant associations (Bonferroni adjusted p-value < 0.05) between
gene expression and cytotoxicity, two from PrediXcan and one from MulTiXcan. Using
PrediXcan, we determined increased predicted expression of STARD5 in the brain cortex tissue
to be associated with a decrease in the concentration of etoposide required for cytotoxicity (IC50)
in the ALL population (p = 8.5 x 10-8) (Figure 7A). Additional results for the YRI population,
etoposide phenotype, and STARD5 derived from other GTEx version 7 and MESA models can
be seen in Table 4. We also found increased predicted expression of USF1 in the liver tissue to
Table 4. STARD5 results for the ALL population and Etoposide cytotoxicity phenotype derived
from GTEx version 7 and MESA models.
Model

P-value

Adj. P

Beta

Brain Cortex
MESA AFHI
MESA HIS
Esophagus Mucosa
MESA ALL
Stomach
Esophagus Muscularis
Skin Sun Exposed Lower leg
MESA CAU
Testis
Artery Tibial
Brain Hippocampus
Esophagus Gastroesophageal Junction
Lung
Muscle Skeletal
Nerve Tibial
Brain Frontal Cortex
Colon Sigmoid
Skin Not Sun Exposed Suprapubic
Cells Transformed fibroblasts

8.5 x 10-8
9.1 x 10-5
3.4 x 10-4
3.6 x 10-3
4.9 x 10-3
4.9 x 10-3
0.018
0.073
0.098
0.11
0.14
0.18
0.19
0.23
0.33
0.33
0.71
0.73
0.91
1.00

0.023
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

-1.1
-2.1
-1.0
-0.66
-0.63
-2.8
-0.92
-0.51
-0.65
0.70
1.6
-0.24
-0.20
-1.6
2.4
-0.69
-4.4
0.15
0.034
0.010

Figure 7. Predicted Expression of significant TWAS gene hits versus measured drug cytotoxicity levels. (A) Predicted
expression of STARD5 in the ALL population as determined by PrediXcan using the GTEx v7 Brain Cortex prediction
model plotted against rank-normalized Etoposide IC50 levels as measured in LCLs from the ALL population. (B) Predicted
expression of USF1 in the ALL population as determined by PrediXcan using the GTEx v7 Liver prediction model plotted
against rank-normalized Capecitabine AUC levels as measured in LCLs from the ALL population. (C) Predicted
expression of CCAR1 in the YRI population as determined by MulTiXcan plotted against rank-normalized Capecitabine
AUC levels as measured in LCLs from the YRI population. CCAR1 expression was best predicted by the GTEx v7
Esophagus Mucosa prediction model. Each point represents an individual, the curved yellow lines convey density in
regard to the distribution of the points, and the purple line is the best fit determined by linear regression, which shows the
direction of effect.
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be associated with an increase in the concentration of capecitabine required for cytotoxicity (AUC)
in the ALL population (p = 8.7 x 10-8) (Figure 7B). Using MulTiXcan, we found increased
predicted expression of CCAR1 to be associated with a decrease in the concentration of
capecitabine required for cytotoxicity (AUC) in the YRI population (p = 4.2 x 10-6) (Figure 7C).
FUMA identifies enrichment in oncogenic signatures
We performed FUMA gene set enrichment analysis on top PrediXcan results for each ancestral
population and drug and found twelve significant gene sets (Table 5) (Watanabe et al. 2017). For
the CEU population and cisplatin, we identified one significant gene set WNT_UP.V1_ UP (p =
1.2 x 10-5). This gene set is an oncogenic signature, denoting up-regulation of the listed genes as
a result of the over-expression of WNT1 in mammary epithelial cells (Ziegler et al. 2005). The
genes making up this set were all found to have predicted expression levels associated with
cisplatin IC50. Cisplatin is often used to treat a variety of cancers, including lung, colon,
testicular, and ovarian cancers (Trendowski, El-Charif, et al. 2019; Trendowski, El Charif, et al.
2019). Additionally, for the CEU population and cytarabine arabinoside (ara-C), we identified
the gene set P53_DN.V1_DN to be significant (p = 1.1 x 10-4). This is another oncogenic
signature, characterized by down-regulation of the genes listed in cancer cell lines with mutated
TP53 from the NCI-60 collection (A. Subramanian et al. 2005). The genes in the set are
impacted by mutations in TP53, a known tumor suppressor gene that, when mutated, can lead to
malignancy (A. Subramanian et al. 2005). The predicted expression levels of these genes are
associated with ara-C AUC.
We also performed FUMA gene set enrichment analysis on top MulTiXcan results for
each ancestral population and drug, which identified fifteen significant gene sets (Table 6). For
the YRI cohort and Daunorubicin, four gene sets, classified as cancer gene neighborhoods, were
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Table 5. Significant Gene Sets from FUMA tool GENE2FUNC generated using top genes from
PrediXcan results.
Pop.

Drug

Category

Gene Set

N

n

Pvalu
e

Adj. P

Genes

CEU

Cisplati
n

Oncogenic
Signatures

WNT_UP.V1_UP

170

7

1.2 x
10-5

0.0023

VAMP1, RPAP3, LTB4R,
SERPINF1, AP2S1,
POMC, HS3ST1

ASN

Capecit
abine

microRNA
Targets
(MsigDB c3)

CCCACAT_MIR2
993P

48

4

1.7 x
10-5

0.0038

RAB6A, ITGAV, ABCE1,
TRPM3

CEU

Capecit
abine

Hallmark Gene
Sets (MsigDB h)

HALLMARK_PE
ROXISOME

100

5

1.1 x
10-4

0.0053

PRDX5, RETSAT,
ABCC5, SEMA3C,
GSTK1

CEU

Paclita
xel

GWAS Catalog
Reported Genes

Liver enzyme
levels (gammaglutamyl
transferase)
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4

8.9 x
10-6

0.015

GSTT2B, DDTL, KB226F1.2, DDT, GGT1

ALL

Carbop
latin

Chemical and
Genetic
Pertubation Gene
Sets

NIKOLSKY_BRE
AST_CANCER_1
7Q21_Q25_AMP
LICON

318

9

4.6 x
10-6

0.016

PDK2, CACNA1G,
SCPEP1, COG1,
FAM104A, C17orf80,
BTBD17, GPRC5C,
SLC16A3

CEU

Paclita
xel

Hallmark Gene
Sets (MsigDB h)

HALLMARK_EPI
THELIAL_MESE
NCHYMAL_TRA
NSITION

190

5

3.2 x
10-4

0.016

VCAM1, COL1A1,
MATN3, CXCL1, ECM2

CEU

Ara-C

Oncogenic
Signatures

P53_DN.V1_DN

179

6

1.1 x
10-4

0.020

AJAP1, KCNAB2,
GPRC5B, HOXB2,
CBX4, DFNA5

51

5

6.5 x
10-6

0.022

PIGV, BBS1, TUBGCP4,
SNX1, CRTC3

153

7

1.5 x
10-5

0.025

BBS1, ZDHHC24, CCS,
LRFN4, RAD9A,
NDUFV1, MTL5

8

5.2 x
10-6

0.025

RRP12, TRMT112,
ACAT1, BTG1, EVL,
MPPE1, FAM161A,
MAPK11

219

8

8.8 x
10-6

0.030

LMO4, TRAF3IP3,
BCL2L11, ABHD12,
IFT122, MSL2, VARS2,
CASC7, AGO2

21

3

7.8 x
10-5

0.034

ABCC4, TWSG1,
CCNE2

ASN

Ara-C

ASN

Ara-C

YRI

Ara-C

ALL

Daunor
ubicin

ASN

Cisplati
n

Chemical and
Genetic
Pertubation Gene
Sets
Chemical and
Genetic
Pertubation Gene
Sets
Immunological
Signatures
(MsigDB c7)
Chemical and
Genetic
Pertubation Gene
Sets
Cancer Gene
Modules
(MsigDB c4)

SOTIRIOU_BRE
AST_CANCER_G
RADE_1_VS_3_
DN
NIKOLSKY_BRE
AST_CANCER_1
1Q12_Q14_AMP
LICON
GSE39110_DAY3
_VS_DAY6_POS
T_IMMUNIZATI
ON_CD8_TCELL
_UP
RICKMAN_TUM
OR_DIFFERENTI
ATED_WELL_V
S_POORLY_UP
MODULE_372

190
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Table 6. Significant Gene Sets from FUMA tool GENE2FUNC generated using top genes from
MulTiXcan results.
Pop.

Drug

Category

Gene Set

YRI

Carbop
latin

GO Cellular Components
(MsigDB c5)

CEU

Daunor
ubicin

GO Cellular Components
(MsigDB c5)

CEU

Ara-C

KEGG (MsigDB c2)

GO_COMPACT_M
YELIN
GO_CYTOPLASMI
C_DYNEIN_COMP
LEX
KEGG_PENTOSE_
PHOSPHATE_PAT
HWAY

Pvalue
7.4 x
10-6

Adj.
P
0.00
43

5

9.3 x
10-6

0.00
54

4

3.7 x
10-5

0.00
68

N

n

15

4

14

22

CEU

Carbop
latin

Immunological
Signatures (MsigDB c7)

GSE4142_GC_BCE
LL_VS_MEMORY_
BCELL_DN

CEU

Carbop
latin

Immunological
Signatures (MsigDB c7)

GSE17721_CPG_V
S_GARDIQUIMOD
_8H_BMDC_DN

193

9

6.9 x
10-6

0.01
7

YRI

Daunor
ubicin

Cancer Gene
Neighborhoods (MsigDB
c4)

GCM_TPT1

66

6

5.3 x
10-5

0.02
3

ALL

Cisplati
n

BioCarta (MsigDB c2)

BIOCARTA_MCM_
PATHWAY

18

3

1.2 x
10-4

0.02
6

YRI

Daunor
ubicin

Cancer Gene
Neighborhoods (MsigDB
c4)

GNF2_EIF3S6

113

7

1.5 x
10-4

0.03
2

Pathways in clear
cell renal cell
carcinoma%WikiPat
hways_20190110%
WP4018%Homo
sapiens

79

6

6.8 x
10-5

0.03
3

0.03
4

189

9

5.8 x
10-6

0.01
7

CEU

Ara-C

WikiPathways

YRI

Daunor
ubicin

Cancer Gene
Neighborhoods (MsigDB
c4)

MORF_ACTG1

126

7

2.9 x
10-4

YRI

Daunor
ubicin

Cancer Gene
Neighborhoods (MsigDB
c4)

MORF_TPT1

91

6

3.2 x
10-4

0.03
4

YRI

Cisplati
n

microRNA Targets
(MsigDB c3)

ACCAATC_MIR50
9

43

5

2.6 x
10-4

0.03
5

Cisplati
n
Capecit
abine
Cisplati
n

microRNA Targets
(MsigDB c3)
GO Cellular Components
(MsigDB c5)

GTAGGCA_MIR18
9
GO_BASAL_PLAS
MA_MEMBRANE
REACTOME_G2_
M_CHECKPOINTS

25

4

32

4

41

4

3.1 x
10-4
6.4 x
10-5
7.1 x
10-5

0.03
5
0.03
7
0.04
8

YRI
ALL
ALL

Reactome (MsigDB c2)

Genes
NCMAP, CD59,
MPP5, PLLP
TPR, DYNLL1,
BCL2L11,
DYNC1LI1, DCTN4
H6PD, PFKM, TKT,
TKTL2
STX6, AMPD3,
ALOX15B, PIGL,
ASAP2, HACL1,
ZNF827, UNC5CL,
C9orf64
LRP8, SLK, AMPD3,
EEF1G, EMC7,
NDRG4, CTDNEP1,
LRRC16A, QKI
RPL27A, RPS3,
NDUFA12, NPM1,
RPS18, RPS10
ORC1, CDC6,
MCM6
PNRC2, RPL27A,
RPS3, EIF3D,
NPM1, RPS18,
RPS10

ARNT, TGFB2, TPI1,
PFKM, MDH1, TSC1

TAGLN2, RPL27A,
ZFPL1, RPS3,
NPM1, RPS18,
RPS10
RPL27A, ZFPL1,
RPS3, NPM1, RPS18,
RPS10
PCDHA2, PCDHA3,
PCDHA4, PCDHA5,
ZFAND3
CAPRIN1, MBLAC2,
SRPK2, MTSS1
SLC27A5, PKD2,
ERBB2IP, CAV1
ORC1, ATM, CDC6,
MCM6
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identified: GCM_TPT1 (p = 5.33e-05), GNF2_EIF3S6 (p = 1.49e-04), MORF_ACTG1 (p =
2.92e-04), and MORF_TPT1 (p = 3.18e-04). Cancer gene neighborhoods develop as a result of
mutations in multiple genes in an area of the genome and are common to some cancer types,
including leukemia. One gene in all four of these sets, RPS18, has been found to be highly
expressed acute lymphoblastic leukemia. Another gene, NPM1, which is also included in each of
these sets, has been found to be upregulated in both acute myeloid and lymphoblastic leukemia.
Daunorubicin is used to treat various subtypes of leukemia, including acute myeloid and
lymphoblastic leukemia, thus it is interesting that the predicted expression levels for the genes
making up these neighborhoods were identified by MulTiXcan to be associated with
Daunorubicin IC50.
Knockdown experiments validate reduced STARD5 expression is associated with reduced
etoposide-induced cytotoxicity
After conducting GWAS and TWAS, we followed up on our results by performing
functional experiments for STARD5, as this gene had the most significant predicted expression
levels from the TWAS results. The predicted expression plot for STARD5 showed a negative
correlation between STARD5 predicted expression and etoposide IC50. Therefore, for our
functional experiments, we hypothesized that the knockdown of STARD5 expression levels
would result in a higher etoposide IC50, which corresponds to lower cellular sensitivity to
etoposide. We selected the lung cancer cell line A549 for the knockdown experiments, as
etoposide is often used to treat lung cancer (Qiu et al. 2019).
After knocking down STARD5 with siRNA, we treated A549 cells with increasing
concentrations of etoposide and then measured relative viability at 72 and 96 hours after
treatment (Figure 8A). siRNA reduced STARD5 expression to less than 25% of control at 0, 72,
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and 96 hours (Figure 8B). At both 72 and 96 hours, reduced STARD5 expression significantly
increased cell viability (Figure 8C-D, p = 0.034 for 72 hours, p = 0.0001 for 96 hours), validating
our TWAS results that higher expression of STARD5 is correlated with greater sensitivity to
etoposide.

Figure 8. Evaluation of the effect of STARD5 knockdown on sensitivity of A549 lung cancer
cells to etoposide. (A) Experimental scheme for knockdown of STARD5 in A549 and treatment
with etoposide. (B) STARD5 expression was reduced < 25% for cells treated with siSTARD5
(gray bars) compared to expression in siSCR (black bars) at time of drug treatment (0H) and at
72 and 96 hours as determined by quantitative reverse transcription PCR (qRT-PCR). Relative
viability, determined by CellTiter-Glo 2.0 assay, for A549 cells treated with increasing
concentrations of etoposide at (C) 72 hours and (D) 96 hours after treatment with siSTARD5
(open circle) or siSCR control (closed circle). Data represents two independent experiments
including at least three replicates analyzed by two-way ANOVA showing the SEM.
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PAS predict seven unique proteins to be significantly associated with chemotherapyinduced cytotoxicity
In addition to GWAS and TWAS, we conducted PAS to identify significant associations
between predicted protein levels and the cytotoxicity of each drug for each ancestral population.
We first predicted protein levels with PrediXcan using the TOPMed prediction models and we
then used GEMMA to perform the association tests, in order to account for relatedness within
each population. We found seven unique proteins with predicted levels significantly associated
with chemotherapy-induced cytotoxicity (Bonferroni adjusted p-value < 0.05) in three of the four
populations (Table 6). In the ASN population, the most significant association identified was
found with the TOPMed EUR model between increased predicted levels of the protein encoded
by NAGK and increased cisplatin concentration required for cytotoxicity (Figure 9A). In the ALL
population, the most significant association identified was found with the TOPMed ALL-M
model between increased predicted levels of the protein encoded by HK2 and decreased
daunorubicin concentration required for cytotoxicity (Figure 9B). In the YRI population, the

Table 7. Significant predicted protein levels from all PAS performed.
Pop.

Drug

Model

Proteincoding Gene

Chr.

P-value

Adj. P

Beta

ASN

Cisplatin

TOPMed EUR

NAGK

2

1.2 x 10-4

0.0065

2.4

2

1.0 x 10

-4

0.015

-3.3

-4

0.015

-4.5

ALL

Daunorubicin

TOPMed ALL-M

HK2

ALL

Pemetrexed

TOPMed CHN

IL17RD

3

5.9 x 10

ALL

Ara-C

TOPMed EUR

DPT

1

1.8 x 10-4

0.016

1.6

3

1.3 x 10

-3

0.036

-5.2

-4

0.038

-1.3

YRI

Pemetrexed

TOPMed CHN

IL17RD

ALL

Daunorubicin

TOPMed ALL-M

EGF

4

2.6 x 10

ALL

Ara-C

TOPMed AFA

IL5RA

3

7.2 x 10-4

0.039

3.9

4

-4

0.042

1.8

YRI

Pemetrexed

TOPMed HIS

PDE5A

4.3 x 10
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most significant association identified was found with the TOPMed CHN model between
increased predicted levels of the protein encoded by IL17RD and decreased pemetrexed
concentration required for cytotoxicity.

Figure 9. Predicted protein levels of significant PAS hits versus measured drug cytotoxicity
levels. (A) Predicted levels of the protein encoded by NAGK in the ASN population as
determined by PrediXcan using the TOPMed EUR prediction model plotted against ranknormalized Cisplatin IC50 levels as measured in LCLs from the ASN population. (B) Predicted
levels of the protein encoded by HK2 in the ALL population as determined by PrediXcan using
the TOPMed ALL-M prediction model plotted against rank-normalized Daunorubicin IC50 levels
as measured in LCLs from the ALL population. Each point represents an individual, the curved
yellow lines convey density in regard to the distribution of the points, and the purple line is the
best fit determined by linear regression, which shows the direction of effect.
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We conducted GWAS, TWAS and PAS for eight chemotherapeutic cytotoxicity
phenotypes measured in LCLs from individuals in three ancestral populations (YRI, CEU, and
ASN) and one combined population (ALL). We identified twelve SNPs at four unique loci, three
genes, and seven proteins significantly associated with chemotherapy-induced cytotoxicity. For
the most significant gene, STARD5, we performed knockdown experiments to follow up on our
finding that increased STARD5 expression associates with decreased etoposide IC50. These
functional experiments validated this result, as knockdown of STARD5 increased viability of
A549 lung cancer cell lines treated with etoposide, demonstrating the positive correlation
between STARD5 expression and cellular sensitivity to etoposide.
The TWAS we conducted identified an association between increased predicted
expression of STARD5 and decreased etoposide IC50, implying a greater cellular sensitivity to
etoposide. This finding was then validated through the knockdown experiments we performed,
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which demonstrated that a reduction of STARD5 expression to twenty-five percent that of
unaltered expression results in increased viability in A549 lung cancer cell lines treated with
etoposide. Etoposide is a chemotherapeutic and antineoplastic drug that targets topoisomerase II,
an enzyme that plays an essential role in DNA replication, recombination, and transcription, by
cutting and pasting double-stranded DNA (Hande 1998). By interfering in topoisomerase II
function in malignant cells, etoposide disrupts necessary biological processes, leading to an
increase in DNA breakage that ultimately induces apoptosis (Hande 1998). Etoposide is
commonly used to treat lung cancer; this informed our selection of the A549 lung cancer cell line
for use in the knockdown experiments to test how etoposide IC50 would be impacted by a
reduction in STARD5 expression (Zucchetti et al. 1995). Additionally, previous projects have
used A549 cell lines to study factors contributing to etoposide-induced cell death (Litwiniec et
al. 2013; Y. Huang et al. 1997).
STARD5 encodes a steroidogenic acute regulatory related lipid transfer domain protein
(Rodriguez-Agudo et al. 2005). Studies have found STARD5 to become more highly expressed
as a response to endoplasmic reticulum (ER) stress, which leads to the relocation of the protein
encoded by STARD5 from the nucleus to the cytosol and cell membrane (Rodriguez-Agudo et al.
2012). Etoposide, while disrupting normal topoisomerase II function, often induces ER stress in
the process (C. Wang et al. 2016). This could contribute to increased STARD5 expression in
cancer cells. Additionally, increased STARD5 expression in hepatocytes has been linked to
increased cholesterol levels (Rodriguez-Agudo et al. 2005). STARD5 protein binds and transports
cholesterol and other sterol-derived molecules in the liver and thus helps regulate lipid
homeostasis and metabolism (Rodriguez-Agudo et al. 2005). The mechanisms for cholesterol
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homeostasis and drug metabolism have been found to rely on the same cellular receptors,
including pregnane X receptor (PXR) (Rezen et al. 2011). PXR binds etoposide as well as other
chemotherapeutics to activate CYP3A4, a key enzyme involved in drug metabolism (Schuetz et
al. 2002). The role of STARD5 in regulating metabolism and other liver functions could be one
explanation for the association between etoposide-induced cytotoxicity and increased STARD5
expression. Etoposide metabolism occurs primarily in the liver, where STARD5 is highly
expressed (Kawashiro et al. 1998; Rodriguez-Agudo et al. 2005). Overall, increased expression
of STARD5, whether preexisting or prompted by ER stress, may facilitate etoposide metabolism
in the liver, in turn promoting etoposide-induced cytotoxicity.
The GWAS we conducted revealed four unique loci associated with cellular sensitivity to
either carboplatin, cisplatin, daunorubicin, or etoposide. In the ASN population, we found three
SNPs on chromosome 9 located within PPP1R26 to be associated with carboplatin-induced
toxicity. PPP1R26 has been associated with tumor formation and is upregulated in breast
carcinomas, promoting metastasis through the degradation of retinoblastoma protein, a tumor
suppressor protein (Zheng et al. 2018; Yang et al. 2005). In the YRI population, we found one
SNP on chromosome 3 located within CNTN4 to be associated with cisplatin-induced toxicity.
CNTN4 encodes a contactin 4, an immunoglobulin that regulates cellular interactions and axonal
growth in the nervous system (Garcia et al. 2020; Evenepoel et al. 2018). Overexpression of
CNTN4 has been found to be associated with malignancy in nerve tissue and with cisplatininduced nephrotoxicity (Garcia et al. 2020; Evenepoel et al. 2018). In the ALL population, we
found two SNPs on chromosome 12 in proximity to AMIGO2 to be associated with etoposideinduced toxicity. AMIGO2 is a scaffold protein that binds to PDK1 to regulate the
phosphoinositide 3-kinase–Akt signaling pathway, which plays a role in many biological
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mechanisms, including cell proliferation and metabolism (H. Park et al. 2015). Overexpression
of AMIGO2 has been found to induce abnormal Akt signaling, which contributes to the onset and
progression of various cancers (H. Park et al. 2015). Additionally, AMIGO2 overexpression is a
common characteristic of metastatic tissue, particularly when metastasis occurs in the liver, as
AMIGO2 regulates cell adhesion in liver cells (Kanda et al. 2017).
The PAS we conducted identified seven unique proteins associated with cellular
sensitivity to either ara-C, cisplatin, daunorubicin, or pemetrexed. In the ASN population we
found N-Acetylglucosamine kinase, encoded by NAGK, to be significantly associated with
cisplatin cytotoxicity. N-Acetylglucosamine kinase is known to regulate the Wnt signaling
pathway, which is involved in metabolism and cell growth and proliferation (Neitzel et al. 2019).
In the ALL population we found Hexokinase II, encoded by HK2, to be significantly associated
with daunorubicin cytotoxicity. Hexokinase II catalyzes the first step in glycolysis and the
upregulation of HK2 in cancer cells has been found to increase the rate of glucose metabolism,
aiding in cell growth and inhibiting apoptosis (Rai et al. 2019). Hexokinase II has been
implicated in several previous cancer studies and has also been used as a target for some recently
developed anticancer therapeutics (Nakajima et al. 2019; S.-J. Wang et al. 2021). Additionally,
the inhibition of Hexokinase II has been found to increase cellular sensitivity to daunorubicin in
myeloid leukemia cells, as this diminishes the protective effects of Hexokinase II against
apoptosis, increasing the likelihood of drug-induced cytotoxicity (Rai et al. 2019). In the ALL
population we also identified interleukin-17 receptor D, encoded by IL17RD, to be associated
with cellular sensitivity to pemetrexed. A previous study found that the downregulation of
IL17RD is common in certain cancer types, such as colon cancers, and can also promote tumor
development (Girondel et al. 2021). We found that the lower predicted levels of interleukin-17
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receptor D associate with a higher concentration of pemetrexed need for cytotoxicity; this is
consistent with these prior findings, as IL17RD functions as a tumor suppressor, thus its
inhibition may result in tumors that are more challenging to treat and require higher dosages of
chemotherapeutics (Girondel et al. 2021).
Additionally, we performed FUMA gene set enrichment analysis on the top genes
identified with TWAS (Watanabe et al. 2017). For CEU and ara-C, we identified enrichment in
the oncogenic signature gene set P53_DN.V1_DN, which consists of genes that are downregulated in cell lines with mutated TP53 (A. Subramanian et al. 2005). Mutations in TP53,
which encodes a tumor suppressor protein, are linked to various cancer types, and the genes in
this set are often down-regulated in cancers where TP53 is also mutated (A. Subramanian et al.
2005). TP53 mutations are known to confer resistance to ara-C (Goldberg et al. 2018; Ko et al.
2019). We also found enrichment in the oncogenic signature WNT_UP.V1_UP for CEU and
cisplatin. This gene set consists of upregulated genes in the Wnt signaling pathway, which is
involved in cell proliferation (Ziegler et al. 2005). Abnormal activation of this pathway can result
in tumor formation and progression (Giles, van Es, and Clevers 2003). For CEU and paclitaxel,
enrichment was found in a GWAS Catalog Reported gene set, containing genes associated with
liver enzyme levels. GGT1 encodes gamma-glutamyl transferase, the main enzyme featured in
this set, which cleaves extracellular glutathione and transfers its components—glutamic acid,
cysteine, and glycine—for intracellular use (Bansal et al. 2019). Upregulation of GGT1 is a
feature of a variety of cancer types, including kidney and ovarian carcinomas (Bansal et al. 2019;
Stordal et al. 2012). Ovarian carcinomas often are treated with combination chemotherapy using
cisplatin and paclitaxel, as these drugs use different mechanisms to induce cell death; however, a
subset of patients develop resistance to one or both of these drugs (Stordal et al. 2012).
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Upregulation of GGT1 was found to be associated with paclitaxel resistance in ovarian cancer
cell lines already resistant to cisplatin (Stordal et al. 2012). Thus, the enrichment of genes in this
set, which are associated with paclitaxel, and the association with GGT1 in particular, may be
understood in the context of this prior finding.
This study has limitations; only the STARD5 TWAS association was functionally
validated, functional studies of the other discovered GWAS, TWAS, and PAS associations have
not yet been attempted. In addition, the functional follow up to the TWAS we conducted utilized
the lung cancer cell line A549 rather than patients with lung cancer or another replication
population. However, the A549 siRNA experiments we performed validated the association
between increased STARD5 expression and increased etoposide-induced cytotoxicity that we
ascertained through TWAS. To fully understand how STARD5 expression impacts the
mechanisms through which etoposide induces cell death, further mechanistic studies are
required. Association studies conducted with proteomic data could enhance these findings
further, as well as additional functional studies that explore links between STARD5 and drug
metabolism. Moreover, if strides towards precision medicine are to continue, studies must
promote greater diversity within participating populations, as currently the majority of human
genome-wide studies are conducted on individuals of European ancestries (Hindorff et al. 2018;
Landry et al. 2018). By studying diseases and drug response in populations with diverse
ancestries data will become more representative of the global population and knowledge of
genetic variants and their role in disease and drug response will be expanded (Landry et al.
2018). In summary, this project successfully identified novel genetic variants involved in
chemotherapy-induced cytotoxicity in diverse ancestral populations through GWAS, TWAS,
PAS, gene set enrichment analysis, and functional gene knockdown experiments.
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